• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Checkpoint Therapeutics Inc.

    3/17/25 4:08:49 PM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CKPT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    CHECKPOINT THERAPEUTICS, INC.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    162828206

    (CUSIP Number)


    03/10/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    162828206


    1Names of Reporting Persons

    Glazer Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,087,052.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,087,052.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,087,052.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.41 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    162828206


    1Names of Reporting Persons

    Paul J. Glazer
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,087,052.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,087,052.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,087,052.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.41 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CHECKPOINT THERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    95 Sawyer Road, Suite 110, Waltham, MA 02453
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Glazer Capital, LLC, a Delaware limited liability company ("Glazer Capital"), with respect to the shares of Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Glazer Capital serves as investment manager (collectively, the "Glazer Funds"); and (ii) Mr. Paul J. Glazer ("Mr. Glazer"), who serves as the Managing Member of Glazer Capital, with respect to the shares of Common Stock held by the Glazer Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock (as defined in Item 2(d)) reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of each of the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.
    (c)Citizenship:

    Glazer Capital is a Delaware limited liability company. Mr. Glazer is a United States citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    162828206
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3,087,052
    (b)Percent of class:

    6.41  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    3,087,052

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    3,087,052

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Glazer Capital, LLC
     
    Signature:Paul J. Glazer
    Name/Title:Paul J. Glazer, Managing Member
    Date:03/17/2025
     
    Paul J. Glazer
     
    Signature:Paul J. Glazer
    Name/Title:Paul J. Glazer
    Date:03/17/2025
    Get the next $CKPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CKPT

    DatePrice TargetRatingAnalyst
    1/13/2025$9.00Buy
    D. Boral Capital
    7/14/2022$7.00Buy
    B. Riley Securities
    1/25/2022$17.00 → $26.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CKPT
    SEC Filings

    View All

    SEC Form 15-12G filed by Checkpoint Therapeutics Inc.

    15-12G - Checkpoint Therapeutics, Inc. (0001651407) (Filer)

    6/9/25 8:05:40 AM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Checkpoint Therapeutics Inc.

    EFFECT - Checkpoint Therapeutics, Inc. (0001651407) (Filer)

    6/5/25 12:15:07 AM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Checkpoint Therapeutics Inc.

    EFFECT - Checkpoint Therapeutics, Inc. (0001651407) (Filer)

    6/5/25 12:15:08 AM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CKPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Fortress Biotech, Inc. sold $129,000 worth of shares (100,000 units at $1.29) and returned $25,101,221 worth of shares to the company (6,122,249 units at $4.10), closing all direct ownership in the company (SEC Form 4)

    4 - Checkpoint Therapeutics, Inc. (0001651407) (Issuer)

    6/3/25 6:34:39 PM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Weiss Michael S was granted 62,195 shares, increasing direct ownership by 36% to 187,007 units (SEC Form 4)

    4 - Checkpoint Therapeutics, Inc. (0001651407) (Issuer)

    5/30/25 11:21:17 AM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Salzman Barry M was granted 12,195 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Checkpoint Therapeutics, Inc. (0001651407) (Issuer)

    5/30/25 11:20:37 AM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CKPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Checkpoint Therapeutics with a new price target

    D. Boral Capital initiated coverage of Checkpoint Therapeutics with a rating of Buy and set a new price target of $9.00

    1/13/25 8:29:55 AM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities resumed coverage on Checkpoint Therapeutics with a new price target

    B. Riley Securities resumed coverage of Checkpoint Therapeutics with a rating of Buy and set a new price target of $7.00

    7/14/22 9:44:00 AM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Checkpoint Therapeutics with a new price target

    HC Wainwright & Co. reiterated coverage of Checkpoint Therapeutics with a rating of Buy and set a new price target of $26.00 from $17.00 previously

    1/25/22 9:58:19 AM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CKPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

    Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025 FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty rev

    5/15/25 4:05:12 PM ET
    $CKPT
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

    UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2025, and recent corporate updates. Recent Corporate Updates: In December 2024, Checkpoint announced that the U.S. Food and Drug Administration ("FDA") approved UNLOXCYT™ (cosibelimab-ipdl) for the tr

    5/13/25 4:15:51 PM ET
    $CKPT
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

    Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint's lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma FDA accepted New Drug Application filing for priority review for CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and adva

    3/31/25 4:05:13 PM ET
    $CKPT
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CKPT
    Financials

    Live finance-specific insights

    View All

    Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

    UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2025, and recent corporate updates. Recent Corporate Updates: In December 2024, Checkpoint announced that the U.S. Food and Drug Administration ("FDA") approved UNLOXCYT™ (cosibelimab-ipdl) for the tr

    5/13/25 4:15:51 PM ET
    $CKPT
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

    WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the fiscal year ended December 31, 2024, and recent corporate updates. Recent Corporate Updates: In March 2025, Checkpoint announced that it entered into an Agreement and Plan of Merger (the "Merger Agreement") with Sun Pharmaceutical Industries, Inc. ("Sun Pharma"), and a wholly owned subsidiary of Sun Pharma, with Checkpoint continuing as the surviving corporation of the transaction and a wholly owned subsidiary of Sun Pharma (the "Merger"). The total transaction value

    3/28/25 8:30:04 AM ET
    $CKPT
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sun Pharma to Acquire Checkpoint Therapeutics

    Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise Will leverage Sun Pharma's global presence toaccelerate patient access to UNLOXCYT™ (cosibelimab-ipdl) Upfront cash payment of $4.10 per share of common stock,representing aggregate upfront consideration of up to $355 million Stockholders will also receive a contingent value right forup to $0.70 per share on achievement of a milestone Acquisition is subject to approval by Checkpoint's stockholdersand other customary closing conditions MUMBAI, India and WALTHAM, Mass., March 9, 2025 /P

    3/9/25 10:06:00 PM ET
    $CKPT
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CKPT
    Leadership Updates

    Live Leadership Updates

    View All

    Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

    WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately. Dr. Sharma currently serves as Vice President of Clinical Development and Therapeutic Head for Nephrology and Hematology at Alexion, AstraZeneca Rare Disease, where he guides and executes the strategic direction of development products and programs within Alexion's nephrology franchise across all stages of development. Prior to joining Alexion, he served as Vice Presiden

    3/18/24 8:00:46 AM ET
    $CKPT
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CKPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Checkpoint Therapeutics Inc.

    SC 13G/A - Checkpoint Therapeutics, Inc. (0001651407) (Subject)

    11/14/24 4:49:25 PM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Checkpoint Therapeutics Inc.

    SC 13D/A - Checkpoint Therapeutics, Inc. (0001651407) (Subject)

    10/1/24 4:15:18 PM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Checkpoint Therapeutics Inc. (Amendment)

    SC 13D/A - Checkpoint Therapeutics, Inc. (0001651407) (Subject)

    5/17/24 5:13:09 PM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care